Psoriasisisachronicinflammatoryskindiseasecharacterizedbyepidermalhyperplasia(Acanthosis)withelongatedridgesandabnormaldifferentiationofepidermalkeratinocytes,dermalangiogenesis,abnormalaccumulationofpolymorphonuclearleukocytes,infiltrationofactivatedTcellsanddendriticcells,andincreasedcytokinelevels.MatTekhasdevelopedinvitromodelofPsoriasistoenablethestudyofthedisease,andtoscreentherapeuticcandidatesforsafetyandefficacy.
Technology:
MatTek’sdiseased3Dmodelofpsoriasisisproducedfromnormalhumanepidermalkeratinocytesandpsoriaticfibroblastsharvestedfrompsoriaticlesions.Thecellsareculturedonspeciallypreparedcellcultureinsertsusingserumfreemediumtoformamultilayered,highlydifferentiatedtissue.ThePsoriasistissuesmaintainapsoriaticphenotypeasevidencedbyincreasedbasalcellproliferation,expressionofpsoriasis-specificMarkersandelevatedreleaseofpsoriasis-specificcytokines.Morphologically,thetissuemodelcloselyparallelslesionalpsoriatichumantissues.Thismodelprovidesresearcherswithahumanrelevant,highlycontrolledinvitromodeltoassessthesafetyandefficacyofleadtherapeuticcompoundsandtostudyotherbasicpsoriasisBIOLOGyphenomena.
Thepsoriasistissuemodelexhibitsapsoriaticphenotypeasevidencedbyincreasedexpressionofpsoriasis-associatedmarkersincludinghumanβ-defensin-2(HBD2),psoriasin,SKALP/elafin,keratinocytehyperproliferativecellsandproinflammatorycytokines/chemokinessuchasIL-6,IL-8,GM-CSF,andIP-10. Additionally,MatTek’sPsoriasismodelcanbeproducedfrom6differentdonorsallowingforthestudyoftherapeuticswhileaccountingforbiologicalvariABIlitybetweendonors.
TheinvitroPsoriasismodelisresponsivetomarketedanti-psoriatictherapeuticsandisamenabletomodelskin–immunesysteminteractionswiththeexogenousadditionofsolubleimmunecellfactors.
Applications:
Anti-PsoriasisDrugScreening
Themodelprovidesresearcherswithauseful,invitromeanstoassessthepre-clinicalsafetyandefficacyofleadtherapeuticcompounds.
PsoriasisApplicationNote
PsoriasisDiseaseResearch
Thetissuemodelcloselyparallelslesionalpsoriatichumantissuesintermsofmorphologyandcytokineexpression.Thismodelprovidesresearcherswithauseful,invitromeanstostudypsoriasisbiologyphenomena.
Searchourlibraryoftechnicalpapersformoreinformation.
TechSpecs:
Tissue:
Kit:ThePsoriasisTissueKit(SOR-300-FT)consistsof24tissues.
Substrate:MilliporeMillicell™Cellcultureinsertused.Poresize=0.4μm,Diameter=0.8cm,Surfacearea=0.6cm2.
Culture:Atairliquidinterface(apicaltissuesurfaceexposedtotheatmosphere).
Histology:8-12celllayersplusstratumcorneum(basal,spinous,andgranularlayers).
LotNumbers:Tissuelotsareproducedeveryotherweekandareassignedaspecificlotnumber.Aletterofthealphabetisappendedtotheendofthelotnumbertodifferentiatebetweenindividualkitswithinagivenlotoftissues.Alltissuekitswithinalotareidenticalinregardstocells,medium,handling,cultureconditions,etc.
Shipment:At2-8°Conmedium-supplemented,agarosegelsin24-wellplates.
Shipmentday:EveryotherMonday.
Delivery:TuesdaymorningviaFedExpriorityservice(US).OutsideUS:Tuesday-Thursdaydependingonlocation.
Shelflife:Includingtimeintransit,tissuesmaybestoredintheiroriginalpackageat2-8°Cforupto4dayspriortouse.Thebestreproducibilitywillbeobtainediftissuesareusedconsistentlyonthesameday,e.g.Tuesdayafternoonorfollowingovernightstorageat2-8°C(Wednesdaymorning).Extendedstorageperiodsarenotrecommended.
Lengthofexperiments:Culturescanbecontinuedforupto2weekswithgoodretentionofnormalepidermalmorphology.Culturesmustbefedeveryotherdaywith5.0mlofSOR-300-FT-MMmedium.Culturestands(MatTekpart#:MEL-STND)arerequiredforexperimentsinexcessof24hrs.
Alternativetissues:
SOR-300-FT-ABF:Antibiotic-freetissue.Forlast3daysofculture,gentamicinisomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.
SOR-300-FT-AFF:Anti-fungal-freetissue.Forlast3daysofculture,Amphotericinisomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.
SOR-300-FT-AFAB:Antibiotic,anti-fungal-freetissue.Forlast3daysofculture,gentamicinandAmphotericinareomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.
SOR-300-FT-CTR:Normalhealthycontroltissueforpsoriasisexperiments
Cells:
Type:Normalhumanepidermalkeratinocytes(NHEK);psoriatichumandermalfibroblasts(PHDF).
Derivedfrom:Neonatal-foreskintissue(NHEK);adultpsoriaticexplants(PHDF)
Screenedfor:HIV,Hepatitis-B,Hepatitis-C,andmycoplasma.
Medium:
Basemedium:Dulbecco’sModifiedEagle’sMedium(DMEM).
Growthfactors/hormones:Epidermalgrowthfactor,insulin,hydrocortisoneandotherproprietarystimulatorsofepidermaldifferentiation.
Serum:None.
Antibiotics:Gentamicin5µg/ml(10%ofthenormalgentamicinlevel).
Anti-fungalagent:AmphotericinB0.25µg/ml.
pHIndicator:Phenolred.
Otheradditives:Lipidprecursorsusedtoenhanceepidermalbarrierformation(proprietary).
Alternatives:Phenolred-free(SOR-300-FT-PRF),antibiotic-free(SOR-300-FT-ABF),anti-fungal-free(SOR-300-FT-AFF),orhydrocortisone-freemediumandtissue(SOR-300-FT-HCF)areavailable.Agentsareremoved3dayspriortoshipment.
Assay/Maintenancemedium:SOR-300-FT-MMisusedforequilibrationoftissuesfollowingshipmentandformaintenanceoftheSOR-300-FTtissuesincultureduringexperiments.
QualityControlandSterility:
Visualinspection:Alltissuesarevisuallyinspectedandifphysicalimperfectionsarenoted,tissuesarerejectedforshipment.
End-usetesting:Tissuesareexposedto1%TritonX-100for4,6,8and10hours.Thetimeofexposurerequiredtoreducethetissueviability(ET-50)usingtheMTTviabilityassayisdetermined(SeeMatTekPsoriasisTissueuseprotocol)foreachlotoftissue.ET-50’sgenerallyfallwithintherangeof6.0-12.0hours.ET-50’sincustomers’labmaydifferslightlyfromtheMatTekresults.Inaddition,qPCRdataforpsoriasisrelatedgeneswillbemonitored.Increasesof>5foldforpsoriasin,humanbeta-defensin-2andelafinareexpected.
Sterility:Allmediausedthroughouttheproductionprocessischeckedforsterility.Maintenancemediumisincubatedwithandwithoutantibioticsfor1weekandcheckedforsterility.Theagarosegelfromthe24-wellplateusedforshippingisalsoincubatedfor1weekandcheckedforanysignofcontamination.
Screeningforpathogens:AllcellsarescreenedandarenegativeforHIV,hepatitisBandhepatitisCusingPCR.However,noknowntestmethodcanoffercompleteassurancethatthecellsarepathogenfree.Thus,theseproductsandallhumanderivedproductsshouldbehandledatBSL-2levels(biosafetylevel2)orhigherasrecommendedintheCDC-NIHmanual,“Biosafetyinmicrobiologicalandbiomedicallaboratories,”1998.Forfurtherassistance,pleasecontactyoursiteSafetyOfficerorMatTektechnicalservice.
Notificationoflotfailure:IfatissuelotfailsourQCorsterilitytesting,thecustomerwillbenotifiedandthetissueswillbereplacedwithoutchargewhenappropriate.BecauseourQCandsterilitytestingisdonepost-shipment,notificationwillbemadeassoonaspossIBLe(Undernormalcircumstances,ET-50failureswillbenotifiedbyThursday5pm;sterilityfailureswillbenotifiedwithin8daysofshipment).
我们的使命：我们致力于推进创新的体外科学并生产协同的生命科学产品和服务，以支持您研究的每一步。
25 年来，MatTek 一直是可靠的体外人体组织模型创新的全球领导者。我们的皮肤、眼部、口腔、呼吸道和肠道组织模型用于评估化妆品、化工、制药和家居用品行业的安全性和有效性。这些先进的组织模型使公司能够实现非动物测试的目标，同时降低测试成本并提供与人类相关的结果。
随着 MatTek 培养皿、原代人类细胞和培养基、3Diy 试剂盒以及为寻求体外解决方案的客户提供测试服务，MatTek 从一家组织工程公司扩展到一家完整的生命科学公司。行业领先的 MatTek 培养皿可在标准尺寸的细胞培养皿和培养板中提供出色的成像。我们在细胞分离和扩增方面的专业知识使我们能够为二维研究开发最高质量的原代人类细胞和培养基。我们的 3Diy 试剂盒通过为研究人员提供以较低成本在 3D 组织模型中使用特化细胞的机会，进一步弥合了 2D 细胞培养和即用型 3D 组织之间的差距。我们在体外科学领域拥有无与伦比的专业知识，并拥有通过我们的测试服务指导客户获得可靠结果的知识。
本网站将在规定时间内给予删除等相关处理。
